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Neutrophils are produced and stored in the 
BM, and the control of neutrophil release from 
BM critically regulates the circulating num-
bers of these cells in blood. Low numbers of 
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Blood neutrophil homeostasis is essential for successful host defense against invading pathogens. 
Circulating neutrophil counts are positively regulated by CXCR2 signaling and negatively regu-
lated by the CXCR4–CXCL12 axis. In particular, G-CSF, a known CXCR2 signaler, and plerixafor, a 
CXCR4 antagonist, have both been shown to correct neutropenia in human patients. G-CSF 
directly induces neutrophil mobilization from the bone marrow (BM) into the blood, but the 
mechanisms underlying plerixafor-induced neutrophilia remain poorly defined. Using a combina-
tion of intravital multiphoton microscopy, genetically modified mice and novel in vivo homing 
assays, we demonstrate that G-CSF and plerixafor work through distinct mechanisms. In contrast 
to G-CSF, CXCR4 inhibition via plerixafor does not result in neutrophil mobilization from the BM. 
Instead, plerixafor augments the frequency of circulating neutrophils through their release from 
the marginated pool present in the lung, while simultaneously preventing neutrophil return to 
the BM. Our study demonstrates for the first time that drastic changes in blood neutrophils can 
originate from alternative reservoirs other than the BM, while implicating a role for CXCR4–
CXCL12 interactions in regulating lung neutrophil margination. Collectively, our data provides 
valuable insights into the fundamental regulation of neutrophil homeostasis, which may lead to 
the development of improved treatment regimens for neutropenic patients.
© 2013 Devi et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
circulating neutrophils (neutropenia) can lead 
to chronic or even life threatening infections 
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from increased neutrophil motility and mobilization from the 
BM, whereas plerixafor had no detectable effects on neutrophil 
migratory activity in this compartment. Instead, we observed 
that plerixafor increased circulating neutrophil numbers by 
blocking neutrophil trafficking to the BM while promoting 
neutrophil release from the lung. In addition, we have also 
examined how the gain-of-function mutations in CXCR4 
influence neutrophil mobilization and homing patterns in vivo. 
Together, these data define distinct mechanisms of neutro-
phil mobilization from different tissue compartments into the 
blood, which provide new insights into neutrophil homeosta-
sis, and may lead to better treatment regimens for neutrophil-
related diseases.
RESULTS
Blood neutrophil frequency is rapidly increased  
after G-CSF or plerixafor treatment
To investigate how G-CSF or CXCR4 inhibition by plerixafor 
may impact neutrophil activity in the BM, we first established 
an intravital imaging model that enabled the visualization of 
these cells within the BM microenvironment of the skull 
(calvarium; Mazo et al., 1998; Fig. 1 a). Our preliminary dy-
namic imaging studies showed that the majority of neutro-
phils in the BM of lysozyme (LysM)-GFP mice (Faust et al., 
2000; Fig. S1) were relatively inactive under homeostatic 
conditions, and neutrophil egress from the BM was a rare 
event (not depicted). We then visualized steady-state neu-
trophil distribution relative to BM sinusoids by examining 
chimeric mice created from irradiated ubiquitous tomato 
fluorescent protein–expressing (mT/mG) mice (Muzumdar 
et al., 2007) that were reconstituted with LysM-GFP BM 
cells, such that their endothelial cells expressed red fluores-
cent protein and neutrophils expressed green fluorescent 
protein. Dynamic imaging of these mice confirmed that neu-
trophils in the marrow space exhibited low baseline motility 
(3 µm/min). However, we also observed that perisinu-
soidal neutrophils displayed an active probing behavior, and 
that a small fraction of these cells successfully transmigrated 
from the abluminal surface of the sinusoidal walls into circu-
lation (Fig. 1 b; Video 1).
Having examined the neutrophil activities in the BM 
under steady-state conditions, we next sought to investigate 
the BM neutrophil response to promobilization signals by 
G-CSF and plerixafor treatments. We first determined the 
appropriate timing for imaging by quantifying the number of 
circulating neutrophils at various time points after G-CSF or 
plerixafor administration (Fig. 1 c). Consistent with previous 
studies, we observed that a single dose of s.c. injection of clin-
ical grade G-CSF (Ulich et al., 1988; Semerad et al., 2002) or 
plerixafor (Martin et al., 2003) resulted in an increase in the 
number of circulating neutrophils. Blood neutrophil counts 
progressively increased over a 4-h period after G-CSF admin-
istration, whereas circulating neutrophil numbers peaked at 
1–2 h and returned to near basal levels by 4 h after plerixafor 
treatment. These results suggest that observable changes of 
neutrophil behavior should occur in the BM within the first 
in human patients if left untreated. Although neutropenia 
can result from a wide range of underlying causes, includ-
ing pathogen exposure, pharmacological insults, and genetic 
factors, the therapeutic options for neutropenic patients 
are limited.
Numerous studies have shown that CXCR2 and CXCR4 
expressed by neutrophils play crucial roles in maintaining 
neutrophil homeostasis (Semerad et al., 2002; Martin et al., 
2003; Suratt et al., 2004; Wengner et al., 2008; Eash et al., 
2010; Köhler et al., 2011b). CXCR2 is important for the 
mobilization of neutrophils from the BM (Suratt et al., 2004; 
Eash et al., 2010; Köhler et al., 2011b; Mei et al., 2012), 
whereas CXCR4 promotes neutrophil retention in the BM 
via interactions with CXCL12 expressed by BM stromal 
cells (Shirozu et al., 1995; Ponomaryov et al., 2000; Eash 
et al., 2010). Accordingly, current treatments for neutropenic 
patients are predominantly directed toward correcting the 
neutrophil deficiency by mobilizing neutrophils to the cir-
culation while also attempting to treat/control the under-
lying infection. Granulocyte-CSF (G-CSF) is widely used 
to treat neutropenic patients in the clinic (Ulich et al., 1988; 
Lieschke and Burgess, 1992a,b), and previous studies have 
demonstrated that G-CSF–induced neutrophil mobilization 
is dependent on CXCR2 signaling (Eash et al., 2010; Köhler 
et al., 2011b). In contrast, transient blockade of CXCR4 
signaling using a small molecule antagonist of CXCR4, 
plerixafor (AMD 3100), has also been shown to induce neu-
trophilia (Martin et al., 2003). Inhibition of CXCR4 sig-
naling by plerixafor was effective in correcting neutropenia 
in a mouse model (Balabanian et al., 2012) and in human 
patients (Dale et al., 2011; McDermott et al., 2011) with 
gain-of-function mutations in CXCR4 that confers the 
warts, hypogammaglobulinemia, immunodeficiency, and my-
elokathexis (WHIM) syndrome (Hernandez et al., 2003). 
This, therefore, provides in vivo evidence to show that CXCR4 
inhibition can be a new and effective treatment for neutro-
penic patients.
The dynamic regulation of circulating neutrophil num-
bers depends on a complex and dynamic interplay between 
various cellular and molecular components in multiple dif-
ferent tissue compartments, and is thus difficult to dissect 
using conventional laboratory techniques. Due to the well 
documented role of CXCR4 in the retention of neutro-
phils and stem cells in the BM niche (Martin et al., 2003; 
Levesque et al., 2004; Eash et al., 2009), CXCR4 inhibition- 
induced neutrophilia is thought to result from increased 
neutrophil egress from the BM (Martin et al., 2003; Suratt 
et al., 2004; Eash et al., 2009, 2010), but this has not been 
demonstrated directly.
To overcome this challenge, we studied neutrophil mobi-
lization using a dynamic and integrative physiological approach. 
We used the technique of intravital multiphoton micros-
copy to directly examine BM neutrophil activity, at the sin-
gle-cell level, in response to G-CSF or CXCR4 inhibition 
by plerixafor treatments in vivo. Here, we provide direct evi-
dence that G-CSF–induced neutrophilia results primarily 
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circulation (Video 2). Our tracking analysis showed that neu-
trophils, at the whole population level, switched from a low 
motility phenotype (mean velocity, 3.28 µm/min; median 
velocity, 2.94 µm/min over a 5-min tracking period) under rest-
ing conditions to a high motility phenotype that peaked at 
25 min after G-CSF injection (mean velocity, 6.51 µm/min; 
median velocity, 6.24 µm/min over a 5-min tracking period; 
Fig. 2 c) and gradually decreased thereafter, but cell migratory 
activity remained elevated for as long as 2 h after administration. 
Additionally, we devised a method to quantify endogenous 
neutrophil egress based on the relative green fluorescent in-
tensity remaining in the marrow space. With this method, we 
observed a decrease of the green fluorescent intensity in the 
marrow space in G-CSF–treated mice, indicating neutrophils 
exiting the BM (Fig. 2 e). This response peaked at 40 min 
after G-CSF administration. It is also interesting to note that 
the GFP intensity recovered to basal levels at later time points 
after G-CSF treatment. Conceivably, this was a result of mi-
grating neutrophils from other regions of the BM replenishing 
the depleted marrow space. Consistent with a previous study 
by Köhler et al. (2011b), we observed that G-CSF–induced 
2 h after treatment. We therefore subsequently designed our 
experiments to image neutrophil responses in the BM from 0 
to 2 h after treatment (Fig. 1 d).
BM neutrophil motility is enhanced by G-CSF
We next imaged the BM microenvironment in LysM-GFP 
mice, in which all myelomonocytic cells are tagged with GFP. 
Neutrophils, however, constitute the major population of these 
GFP-positive cells (>70%), and they exhibit the highest GFP 
expression (Fig. S1). Consequently, neutrophils can be easily 
distinguished from other myelomonocytic cell types based on 
their high GFP intensity (Chtanova et al., 2008; Peters et al., 
2008; Kreisel et al., 2010; Ng et al., 2011; Li et al., 2012). In 
addition, the BM sinusoids were visualized by intravenous 
injection of TRITC-dextran (Fig. 2 a). Increased neutrophil 
motility was detected within 11 min after a single s.c. injec-
tion of G-CSF (mean = 10.63 min ± 0.31 SD, n = 3; Fig. 2 b). 
These data are in agreement with a previous study of G-CSF 
effects on neutrophil motility in tibial BM (Köhler et al., 2011b). 
In mice that received G-CSF, neutrophils were observed to 
migrate toward the sinusoids before exiting into the blood 
Figure 1. Intravital multiphoton micros-
copy of murine skull BM. (a) Schematic 
overview of the imaging region of mouse 
skull. (Left) Set-up of an anaesthetized mouse 
on a custom-made intravital imaging stage. 
(Middle) Removal of skin and exposure of the 
skull bone. (Right) A snapshot of the skull BM 
microenvironment in a LysM-GFP mouse, 
consisting of GFP+ neutrophils (green), sinu-
soids (vasculature labeled with TRITC dextran; 
red), and bone collagen matrix (second har-
monic generation; blue). Bar, 200 µm.  
(b) Representative time-lapse images showing 
resting state neutrophil activity in skull BM in 
a chimeric mouse (LysM-GFP BM transferred 
into irradiated mT/mG mice; n = 3 mice). The 
white box specifies the region viewed at high 
magnification (bottom). The arrow indicates 
the direction of blood flow, and arrowheads 
indicate GFP+ neutrophils migrating through 
the sinusoidal endothelium (red), followed by 
their release into the circulation (white 
dashed line). Time scale (minutes:seconds) is 
shown above images. Bars, 40 µm. See also 
Video 1. (c) Kinetics of circulating neutrophil 
numbers in WT mice in response to a single  
s.c. injection of 250 µg/kg G-CSF or 5 mg/kg 
plerixafor treatment (n = 4 mice per group 
per time point). All data are shown as mean ± 
SEM. A representative set of data were shown 
from three independent experiments. (d) The 
experimental procedure for multiphoton im-
aging of the skull BM. This involved prepara-
tion of the mouse followed by 2 h of imaging, 
which involved 10 min of basal imaging and 
post–G-CSF or -plerixafor s.c. injection.
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monocyte migratory activity was not enhanced after G-CSF 
injection in CX3CR1-GFP mice subjected to the same BM 
imaging protocol (Fig. 2 f).
neutrophil motility is dependent on CXCR2 (unpublished 
data), and that the observed increase in cell motility after 
G-CSF treatment was restricted to neutrophils because BM 
Figure 2. Neutrophil motility in skull BM 
is increased by G-CSF but not by plerixafor. 
(a) Snapshots of migrating neutrophils in the 
BM of LysM-GFP mice during resting state (top 
left), and 25 min after G-CSF injection (top 
right). White boxes and circles indicate the 
region of GFP+ neutrophil mobilization from 
the BM cavity toward the sinusoids (vascula-
ture labeled with TRITC dextran; red). (Bottom) 
Same images as in the top, with the green sig-
nal (neutrophils) omitted. White lines indicate 
the tracks of migrating neutrophils over the 
10-min imaging period. Bars, 40 µm. (b) Mean 
instantaneous velocity of migrating GFP+ neu-
trophils in skull BM in a LysM-GFP mouse both 
before and after G-CSF (representative of three 
independent experiments). (c) The mean migra-
tory velocities (top) and the relative frequency 
distribution of neutrophil velocities (bottom)  
at different time points after G-CSF injection 
(5-min tracking period, n = 3 per group). Each 
symbol corresponds to an individual tracked 
neutrophil and the bars indicate the mean  
velocity during resting, 25 min and 50 min post-
G-CSF injection. (d) Snapshots of neutrophils in 
BM during resting state (left) and after plerixa-
for treatment (5 mg/kg s.c.; right). White lines 
indicate the tracks of neutrophils over the 1-h 
tracking period after plerixafor injection (vascu-
lature labeled with TRITC dextran, red). Bars,  
40 µm. (e) Relative GFP fluorescence intensity in 
the skull BM parenchymal region in LysM-GFP 
mice treated with G-CSF or plerixafor over time 
(representative of three independent experi-
ments). (f) Mean instantaneous velocity of mi-
grating monocytes in the BM of CX3CR1-GFP 
mouse after G-CSF treatment. Graph shows a 
representative dataset from three independent 
experiments. The arrow indicates the time point 
whereby G-CSF was administered s.c. (g, Top) 
Mean instantaneous velocity of migrating GFP+ 
neutrophils in skull BM in a LysM-GFP mouse 
at resting state and after plerixafor treatment 
(data from three independent experiments).  
(g, Middle) The mean migratory velocities of 
neutrophils at different time points after plerix-
afor injection (30-min tracking period, n = 3 
per group). (g, Bottom) The relative frequency 
distribution of neutrophil velocities (dataset 
from a representative mouse). Each symbol 
corresponds to an individual tracked neutrophil 
and the bars indicate the mean velocity of the 
whole population. A Student’s two-tailed un-
paired t test was performed. Numbers above 
the frequency distributions indicate the median 
velocity of the population. PI = post-injection, 
n.s. = not significant. See also Video 2.
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exit from the BM during the entire imaging period (up to 2 h 
after drug administration, Fig. 2 e). Despite inducing profound 
blood neutrophilia, administration of plerixafor had no de-
tectable effect on the migratory behavior of BM neutrophils 
(Fig. 2, e and g; Video 2). To exclude the possibility that these 
differential neutrophil responses to G-CSF and plerixafor were 
specific to the skull BM, we performed additional imaging 
experiments in tibial BM (Köhler et al., 2011a,b). Neutrophils 
in tibial BM displayed similar mobilization responses to their 
skull BM counterparts; G-CSF injection increased cell motility 
whereas plerixafor treatment did not (unpublished data). These 
data confirmed that neutrophil mobility in the skull BM displays 
similar characteristics to BM neutrophils at other sites. Based 
on these results, we therefore used the model of the skull BM 
for our subsequent imaging studies, as the skull BM set-up is 
more robust and less surgically invasive than the tibial model.
Thus, despite exerting different influences on BM neu-
trophil activity, both G-CSF and plerixafor were capable of 
Neutrophilia induced by CXCR4 inhibition  
is independent of mobilization from the BM
Interactions between CXCR4 and CXCL12 promote neutro-
phil retention in the BM and contribute to neutrophil ho-
meostasis (Martin et al., 2003; Suratt et al., 2004; Eash et al., 
2010). Accordingly, inhibition of CXCR4 signaling by plerix-
afor is thought to induce peripheral neutrophilia by increasing 
neutrophil release from the BM (Martin et al., 2003; Broxmeyer 
et al., 2005). However, a recent study has suggested that pleri-
xafor treatment can increase blood neutrophil frequency by 
mobilizing neutrophils from sites other than the BM (Balabanian 
et al., 2012). To assess whether CXCR4 inhibition-induced 
neutrophilia is derived from the BM, we first performed dy-
namic imaging experiments on BM in LysM-GFP mice after 
plerixafor administration. Contrary to our initial expectations, 
we observed no change in the migratory behavior of neutro-
phils after plerixafor treatment (Fig. 2 d). Neutrophils failed to 
migrate toward the sinusoids and no cells were observed to 
Figure 3. Differential effects of G-CSF 
and plerixafor on neutrophil mobilization 
in vivo. (a) A schematic representation of the 
two models established to study neutrophil 
egress (from BM to blood) and neutrophil 
ingress (from blood to BM). (b, Top) Experi-
mental model 1: BM cells from LysM-GFP mice 
were transferred into WT recipient mice at 
least 4 h before multiphoton imaging of the 
skull BM. Recipient mice were subsequently 
injected with PBS, G-CSF, or plerixafor s.c., 
followed by imaging for up to 2 h (n = 5 per 
group). (b, Bottom) A representative snapshot 
of the skull BM 4 h after cell transfer. GFP+ 
cells (green) were predominantly present in 
the BM cavity outside the sinusoids (labeled 
with TRITC dextran; red). Bar = 200 µm.  
(c) Mean instantaneous velocities of trans-
ferred GFP+ neutrophils in mice treated with 
G-CSF or plerixafor. Each graph shows a data-
set from a representative mouse. (d) Mean 
GFP+ neutrophils egressed from the skull BM 
after PBS, G-CSF, or plerixafor treatment (n = 5 
per treatment group). All data are shown as 
mean ± SEM. One-way ANOVA analysis was 
performed. (e) The frequency distribution of 
neutrophils egressed from the BM into the 
sinusoidal circulation at various time points 
after G-CSF or plerixafor injection. Analysis 
was performed on data pooled from five mice 
per treatment group. See also Videos 3–5.  
(f) The number of circulating GFP+ neutrophils 
before and after G-CSF (left) or plerixafor 
(right) treatment (n = 4 per group per time 
point). Each line corresponds to a single mouse 
and shows the number of circulating neutro-
phils at resting state and 2 h after G-CSF or 
plerixafor treatment. Student’s two-tailed 
paired t test was performed. *, P < 0.05; **, P < 
0.01; ***, P < 0.001; n.s. = not significant.
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observation, our intravital imaging experiments also showed 
that plerixafor pretreatment augmented KC-induced neutro-
phil egress from the BM (unpublished data). We also observed 
that neutrophils which had eventually egressed from the BM 
were responding from distances further away from the sinu-
soids (Fig. 4 b and Video 6). Conceivably, blockade of the 
CXCR4 retention force allowed the neutrophils to become 
more responsive to KC stimulation. Together, our findings 
suggest that CXCR4 inhibition does not play a direct active 
role in neutrophil egress but instead lowers the threshold for 
mobilizing neutrophils from the BM.
Impaired neutrophil trafficking to the BM after plerixafor 
treatment increases circulating neutrophils
To visualize neutrophil trafficking to the BM, we infused 
freshly isolated LysM-GFP+ BM cells into WT recipient mice 
through the cannulated jugular vein 1 h after treatment with 
G-CSF or plerixafor (Fig. 5 a, experimental model 2). This 
approach allowed us to directly visualize the activities of GFP+ 
neutrophils from the time of first appearance in the micro-
circulation of the skull BM. In PBS-injected control mice and 
G-CSF–treated mice, the transferred GFP+ neutrophils were 
observed to adhere to the luminal surface of the BM sinusoi-
dal walls as early as 30 min after transfer, followed by trans-
migration into the BM parenchyma (Fig. 5 b and Video 7). 
Under these conditions, neutrophil transmigration into the 
BM compartment reached a plateau within 2 h of cell trans-
fer (unpublished data). In contrast, GFP+ neutrophil rolling 
along the vessel walls rarely resulted in recruitment into 
the BM parenchyma in plerixafor-treated mice (Fig. 5 b and 
Video 7). This result was confirmed by quantitative image analy-
sis demonstrating a significant reduction in GFP+ neutrophils 
in BM parenchyma of plerixafor-treated animals compared 
with either G-CSF–treated mice or PBS-injected control 
animals (Fig. 5 c). The inhibition of GFP+ neutrophils trafficking 
inducing marked increase in circulating neutrophil numbers 
(Fig. 1 c). To better define the mechanisms that account for 
this finding, we established two independent experimental 
models which examine how G-CSF and plerixafor treatment 
influenced neutrophil egress (BM to blood; experimental 
model 1) and neutrophil ingress (blood to BM; experimental 
model 2; Fig. 3 a). We used exogenously transferred GFP+ 
neutrophils to overcome the technical challenge of tracking 
endogenous BM neutrophils, as it is difficult to distinguish 
individual cells within the congested marrow space.
Neutrophil entry and exit from the BM are likely to con-
tribute to the regulation of blood neutrophil counts (Løvås 
et al., 1996; Suratt et al., 2001; von Vietinghoff and Ley, 2008). 
Thus, we sought to correlate the rate of neutrophil exit from 
the BM with the neutrophil frequency in blood. In the egress 
model, freshly isolated LysM-GFP+ BM cells were adoptively 
transferred into WT recipient mice and subsequently allowed 
to reach steady-state localization into the BM for a mini-
mum of 4 h before administration of G-CSF or plerixafor and 
subsequent BM imaging was performed (Suratt et al., 2001; 
Fig. 3 b, experimental model 1). G-CSF treatment increased 
the motility of adoptively transferred GFP+ neutrophils in the 
skull BM with comparable efficacy to the effects previously 
observed with endogenous neutrophils in LysM-GFP mice 
(Fig. 3 c). Administration of G-CSF triggered the redistribu-
tion of GFP+ neutrophils toward BM sinusoids and promoted 
the release of these cells into the circulation (Fig. 3 d; Video 3). 
The release of GFP+ neutrophils from the BM peaked be-
tween 30 and 50 min after G-CSF administration (Fig. 3 e) and 
closely mirrored the increase in GFP+ neutrophils detected in 
the blood (Fig. 3 f). These findings indicate that neutrophil 
egress from the BM contributed to the number of circulating 
neutrophils in the blood of G-CSF–treated mice. In contrast, 
plerixafor treatment did not alter the motility of GFP+ BM 
neutrophils (Fig. 3 c). The rate of neutrophil egress from the 
BM in response to plerixafor was comparable to that observed 
at baseline (Fig. 3, d and e; Videos 4 and 5). However, plerixa-
for administration still led to a substantial increase of GFP+ 
neutrophils detected in the circulation (Fig. 3 f). These data 
suggest that although G-CSF stimulates neutrophil egress 
from the BM, the rapid increase in circulating neutrophils 
after CXCR4 inhibition by plerixafor treatment is largely in-
dependent of mobilization from this compartment.
CXCR4 does not play a direct active role  
in the mobilization of neutrophils
To further dissect out the contributions of CXCR2 and 
CXCR4 in neutrophil mobilization from the BM, we exam-
ined how transient inhibition of CXCR4 may influence 
KC-induced (KC, a CXCR2 ligand) neutrophil mobilization. 
As shown in Fig. 4 a, we observed that transient CXCR4 in-
hibition by plerixafor has a synergistic effect on KC-induced 
neutrophilia when a suboptimal dose of KC was adminis-
tered. This synergistic effect by plerixafor diminished when 
higher concentrations were applied, indicating that CXCR2 
is the dominant axis for neutrophil egress. Consistent with this 
Figure 4. Role of CXCR2 and CXCR4 in KC-induced neutrophilia. 
(a) WT mice were pretreated for 1 h s.c. with plerixafor before i.v. treat-
ment of KC at different doses. Number of circulating neutrophils detected 
2 h after KC administration (n = 5 per group per dose). The control group 
consists of mice treated i.v. with KC only at specified doses. A representa-
tive set of data were shown from two independent experiments. All data 
are shown as mean ± SEM. (b) The mean traveling distance of neutrophils 
from the BM parenchyma to the sinusoids before egression. This was 
measured in LysM-GFP mice pretreated for 1 h with s.c. PBS or plerixafor 
after i.v. KC administration (500 ng per mouse). Graph shows dataset 
from a representative mouse (n = 3 per group). See also Video 6. All data 
are shown as mean ± SEM. A Student’s two-tailed unpaired t test was 
performed. *, P < 0.05.
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treated cells into untreated recipient mice for subsequent imag-
ing (Fig. 5 d). We observed that BM neutrophils from plerixa-
for-treated mice lacked the ability to traffic back to the BM 
at 2 h after transfer. This was further validated by flow cytome-
try experiments, whereby we observed that plerixafor-treated 
to the BM in plerixafor-treated mice was accompanied by a 
reciprocal increase in circulating GFP+ neutrophil frequency 
(Fig. 5 c). To further understand if plerixafor acts directly on 
the neutrophils, we isolated LysM-GFP+ BM neutrophils from 
mice pretreated with plerixafor for 1 h before transferring these 
Figure 5. CXCR4 blockade inhibits neutrophil trafficking 
to the BM. (a) Experimental model 2: recipient WT mice were 
pretreated for 1 h s.c. with PBS, G-CSF, or plerixafor (n = 6 per 
group) before receiving BM cells from LysM-GFP mice via the 
cannulated jugular vein. (b) Representative time-lapse images 
showing neutrophil trafficking to the BM in PBS-treated mice 
(top), G-CSF–treated mice (middle) or plerixafor-treated mice 
(bottom). Arrows indicate GFP+ neutrophils (green) transmi-
grated from sinusoids (labeled with TRITC dextran; red) into the 
marrow space (black region). Bars, 40 µm. See also Video 7.  
(c, Left) Quantification of GFP+ neutrophils in skull BM cavity 2 h 
after treatment. (c, Right) Number of circulating GFP+ neutro-
phils 2 h after G-CSF or plerixafor treatment (n = 6 per group). 
Each symbol corresponds to one mouse and the bars represent 
mean GFP+ neutrophil numbers in each treatment group.  
(d, Left) The experimental procedure involved donor LysM-GFP 
mice pretreated for 1 h with s.c. PBS or plerixafor before trans-
ferring isolated treated BM cells into WT recipient mice via the 
cannulated jugular vein during imaging. (d, Right) Quantification 
of PBS-treated and plerixafor-treated GFP+ neutrophils in skull 
BM cavity 2 h after transfer (n = 4–5 per group). All data are 
shown as mean ± SEM. A Student’s two-tailed unpaired t test 
was performed. **, P < 0.01; n.s. = not significant. (e) Recipient 
WT mice were pretreated for 1 h s.c. with PBS or plerixafor  
before receiving i.v. BM cells from LysM-GFP mice. 1–4 h after 
transfer of GFP+ BM cells, blood and perfused femur were col-
lected and assessed via flow cytometry. (e, Left) The number of 
GFP+ neutrophils detected in the recipient BM. (e, Right) The 
number of circulating GFP+ neutrophils 1–4 h after transfer of 
BM cells (n = 4 per group per time point). A representative set of 
data were shown from two independent experiments. All data 
are shown as mean ± SEM.
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indicating minimal neutrophil egress in response to G-CSF in 
the WHIM-LysM-GFP mice (Fig. 6 c). In addition, we also 
noted that plerixafor did not have an impact on neutrophil 
motility (not depicted) and egress in the WHIM-LysM-GFP 
mice (Fig. 6 c).
Plerixafor inhibits trafficking of CXCR4mut neutrophils  
to the BM in similar manner as to wild-type neutrophils
To better define the role of CXCR4 in the retention of neu-
trophils in the blood, we compared the mobilization ability of 
the CXCR4 gain-of-function neutrophils versus wild-type 
neutrophils using the ingress model established earlier (experi-
mental model 2, see Fig. 3 a). This was performed by transfer-
ring a 1:1 ratio of selected Ly6G+ cells from the donor BM of 
both WHIM-LysM-GFP and WT-mT/mG mice into WT 
recipients pretreated for 1 h with PBS or plerixafor (Fig. 7 a). 
This method allowed us to easily detect and distinguish the 
two different fluorescent-tagged neutrophils in the recipient 
mice via flow cytometry. We observed that the circulating 
WHIM-LysM-GFP+ neutrophil counts were significantly in-
creased when mice were treated with plerixafor (Fig. 7 b). This 
increase in circulating neutrophils after plerixafor treatment 
was also observed with the WT-mT/mG+ neutrophils. In con-
trast, in the BM of plerixafor-treated mice, we detected a signifi-
cant reduction of both WHIM-LysM-GFP+ and WT-mT/mG+ 
LysM-GFP+ neutrophils were gradually detected in the BM 
over a period of 4 h that corresponds to a gradual reduction of 
these cells in the circulation (Fig. 5 e). Together, these data dem-
onstrate that circulating neutrophil numbers can be increased 
dramatically by inhibiting homing of these cells to the BM.
Gain-of-function CXCR4 mutations altered  
neutrophil mobilization from the BM
To further understand the role of CXCR4 in neutrophil 
mobilization, we examined a CXCR4 gain-of-function ge-
netic mouse model, i.e., an animal model for WHIM syndrome 
(Balabanian et al., 2012). For these experiments, we crossed 
the WHIM mouse onto LysM-GFP background to directly 
visualize how the gain-of-function mutations in CXCR4 may 
influence BM neutrophil activities and how plerixafor may 
act on these cells. We observed that although G-CSF was able to 
increase neutrophil motility in the BM of WHIM-LysM-GFP 
mice in a similar fashion as to the wild-type mice (Fig. 6 a), 
the mutant neutrophils displaced less as compared with their 
wild-type counterparts (Fig. 6 b). These results suggest that 
the CXCR4 gain-of-function mutation renders neutrophils 
less responsive to G-CSF–mediated egress signals. Consistent 
with this, quantification of the relative green fluorescent in-
tensity in the BM also showed that the green fluorescent in-
tensity remained relatively constant over the observation period, 
Figure 6. Neutrophil egress in LysM-GFP 
and WHIM-LysM-GFP mice. (a) Mean neu-
trophil migratory velocities at 25 min after  
G-CSF injection in skull BM of LysM-GFP and 
WHIM-LysM-GFP mice (5-min tracking period, 
n = 3 per group). Each symbol corresponds to 
an individual neutrophil tracked and the bars 
represent mean migratory velocity of each 
group. A Student’s two-tailed unpaired t test 
was performed. n.s. = not significant. (b) Dis-
placement of migrating GFP+ neutrophils 
(relative to their initial positions) in LysM-GFP 
and WHIM-LysM-GFP mice during basal (left) 
and 25 min after G-CSF injection (right; 5-min 
tracking period, n = 3 per group). All data are 
shown as mean ± SEM. (c) Relative GFP fluor-
escence intensity in the skull BM parenchy-
mal region in LysM-GFP and WHIM-LysM-GFP 
mice treated with G-CSF (left) or plerixafor 
(right) over time (representative of three inde-
pendent experiments).
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induce rapid demargination of neutrophils from the lungs 
(Bierman et al., 1952b). This set of experiments showed that 
indeed, epinephrine treatment increases neutrophil release from 
the lungs (Fig. 8 b).
In plerixafor-treated mice, neutrophil frequency was sig-
nificantly increased in arterial blood compared with venous 
blood, which peaked between 2 and 4 h after treatment and 
returned to basal level after 6 h. In contrast, G-CSF only had 
an effect on marginated neutrophils in the lung at a later time 
point (Fig. 8 c), and it is conceivable that the mechanism of 
action is through the down-regulation of CXCR4 expres-
sion (Kim et al., 2006). Indeed, we observed that after G-CSF 
treatment, neutrophils down-regulate CXCR4 expression 
gradually (unpublished data).
In addition, we have also determined the expression of 
CXCR4 ligand, CXCL12, in the lung using a CXCL12-GFP 
mice (Ara et al., 2003). By flow cytometry, we observed that 
CXCL12 is expressed by a fraction of endothelial cells, and with 
immunofluorescence staining of the lungs, we observed that 
CXCL12 is primarily expressed by capillary endothelial cells 
(Fig. 8 d). Collectively, these data indicate that the CXCR4–
CXCL12 interactions contribute to the neutrophil margination 
and demargination process in the pulmonary circulation.
Having shown the increased release of neutrophils and 
expression of CXCL12, we next sought to visualize demar-
gination of lung neutrophils in response to CXCR4 inhi-
bition. We analyzed neutrophil activity in the subpleural 
capillaries of LysM-GFP mice using an intravital lung imag-
ing model described recently (Looney et al., 2011; Fig. 8 e). 
Consistent with previous studies (Lien et al., 1987; Doyle 
et al., 1997; Kreisel et al., 2010; Looney et al., 2011), we ob-
served a large number of marginated neutrophils within the 
pulmonary circulation under resting conditions. Adminis-
tration of plerixafor triggered a reduction in the number of 
marginated neutrophils in the lungs within 2 h (Fig. 8 e). In 
contrast, the effects of G-CSF on marginated neutrophil 
numbers were negligible within this time frame, consistent 
with the neutrophil release data (Fig. 8 c and Video 8). As 
it is technically challenging to preserve the lungs under 
physiological conditions, each imaging field was imaged for 
neutrophils. Collectively, this set of data demonstrates that the 
CXCR4 mutant neutrophils respond similarly to wild-type 
neutrophils during plerixafor treatment by increasing their 
retention in blood while preventing neutrophils from traf-
ficking back to the BM.
Neutrophils are released from the pulmonary  
circulation in response to plerixafor
Our data showed that release of neutrophils from the BM com-
partments does not have a major role in plerixafor-induced 
neutrophilia, pointing to the possibility of alternative neutro-
phil sources. The lungs accumulate a large pool of transit- 
delayed (marginated) neutrophils under normal physiological 
conditions (Doerschuk et al., 1987; Lien et al., 1987; Kuebler 
et al., 1994; Doyle et al., 1997; Kreisel et al., 2010) established 
by the differentially increased resistance of the pulmonary 
microvascular bed toward neutrophils. Under physiological 
state, when dynamic equilibrium is expected (i.e., neutrophil 
influx equals neutrophil efflux), the reservoir of excess re-
tained neutrophils forms the lung marginated pool. The 
concentration of neutrophils present in the pulmonary micro-
vascular bed is thought to be 20–60× higher than that pres-
ent in the large systemic vessels (Lien et al., 1987; Hogg et al., 
1994), and the lung has been estimated to hold up to 10–30% 
of total blood volume (Dock et al., 1961). Thus, the release of 
neutrophils from the marginated pool in the lung could rea-
sonably be expected to exert a significant impact on circulat-
ing neutrophil numbers.
We therefore sought to determine whether G-CSF and 
plerixafor treatments were capable of triggering the release of 
marginated neutrophils from the lungs to reenter the circula-
tion. To achieve this, we devised a tandem sampling method 
of obtaining both arterial blood (carotid) and venous blood 
(inferior vena cava) while preserving the ventilation and per-
fusion of the lungs in live mice (Fig. 8 a). This approach allowed 
us to perform differential counts of neutrophils in arterial blood 
(exiting the lung) and venous blood (entering the lung) while 
avoiding the potential influence of interposing organs on 
neutrophil numbers. To validate our tandem sampling method, 
we used epinephrine as a positive control, which is known to 
Figure 7. Neutrophil mobilization patterns of WHIM-LysM-GFP and WT-mT/mG mice. (a) The experimental procedure involved selection of 
Ly6G+ cells from BM cells isolated from donor WHIM-LysM-GFP and mT/mG mice. Cells were subsequently i.v. transferred in a 1:1 ratio into WT recipient 
mice pretreated for 1 h s.c. with PBS or plerixafor. 2 h after transfer of fluorescent-tagged cells, blood and perfused femur were collected. (b, Left) The 
normalized number of circulating fluorescent-tagged neutrophils 2 h after transfer. (b, Right) The normalized number of fluorescent-tagged neutrophils 
detected in the recipient BM (n = 4–5 per group). A representative set of data were shown from two independent experiments. All data are shown as 
mean ± SEM. Student’s two-tailed unpaired t test was performed. ***, P < 0.001.
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Figure 8. Plerixafor demarginates neutrophils from 
the lung through increase in net neutrophil release.  
(a) A schematic representation of the simultaneous blood 
sampling method. Arrows indicate the direction of blood flow 
(blue = venous blood entering the lung; red = arterial blood 
exiting the lung). X indicates the carotid artery and inferior 
vena cava sites of blood collection. Mice received PBS, G-CSF, 
or plerixafor s.c., followed by the collection of blood samples 
from the cannulated carotid artery and vena cava 2 h after 
treatment (n = 5–7 per group per time point). Net neutrophil 
numbers released from lung were calculated using the for-
mula indicated. (b, Left) Kinetics of circulating neutrophil 
numbers in WT mice in response to i.p. injection of 1 mg/kg 
epinephrine treatment (n = 4 mice per group per time point). 
All data are shown as mean ± SEM. (b, Right) Net neutrophil 
release from lungs 2 h after saline or epinephrine treatment. 
Each symbol corresponds to one mouse (n = 7–9 per group) 
and the bars represent mean neutrophil numbers in each 
treatment group. A Student’s two-tailed unpaired t test was 
performed. **, P < 0.01. (c) Kinetics of net neutrophil release 
from lungs of mice treated s.c. plerixafor (left) or G-CSF 
(right; n = 6–8 per group per time point). Control group 
consists of mice treated s.c. with PBS. All data are shown as 
mean ± SEM. A Student’s two-tailed unpaired t test was 
performed. **, P < 0.01; n.s. = not significant. (d, Left) A rep-
resentative flow cytometry plot showing the endothelial 
marker, CD31, and GFP expression in lung cells of WT (top) 
and CXCL12-GFP (bottom) mice (n = 3 per group). (d, Right) 
Confocal images of lung sections from CXCL12-GFP demon-
strating GFP expression in subpleural area (apical; left) and 
secondary bronchiole (middle, right). Images are representa-
tive of three independent experiments. Bars, 25 µm. C: capil-
lary; Al: Alveoli; Br: Bronchiole; Bv: blood vessel. (e, Top) The 
experimental procedure for intravital imaging of the lung. 
Mice were pretreated for 90 min with PBS, G-CSF, or plerixa-
for s.c., followed by imaging using spinning-disk confocal 
microscopy. Five different fields from each lung were imaged 
for 5 min each. (e, Bottom) Quantification of neutrophils 
adhering to the pulmonary capillaries over the 5-min obser-
vation period in PBS-, G-CSF–, and plerixafor-treated mice  
(n = 6 per group). Each symbol corresponds to data obtained 
from an individual mouse and the bars represent the mean 
number of adherent neutrophils in each treatment group. 
See also Video 8. (f, Top) Experimental procedure for intravital 
multiphoton imaging of skeletal muscle involved preparation 
of the LysM-GFP mouse, followed by 1 h of imaging after s.c. 
injection of PBS, G-CSF, or plerixafor. (f, Bottom) The dura-
tion of neutrophil adherence measured in 100-µm lengths of 
muscle capillaries (3–6 capillaries, 4–7 µm in diameter) of 
LysM-GFP mice treated s.c. with PBS, G-CSF, or plerixafor  
(n = 3 per group). All data are shown as mean ± SEM. One-
way ANOVA analysis was performed in e and f. *, P < 0.05;  
**, P < 0.01; n.s. = not significant. See also Video 9.
5 min and the data were presented as binary events. To fur-
ther validate our data, we performed additional experiments 
to investigate neutrophil margination in the microcircula-
tion of skeletal muscle in mice. This was done by measuring 
the overall dwell time of neutrophils along muscle capillaries 
(over the length of 100 µm). This approach allowed us to bet-
ter examine the dynamic behavior of neutrophil margination 
in vivo, and we observed that plerixafor reduced neutro-
phil dwell time within the capillaries of muscle (Fig. 8 f  
and Video 9). This suggests that plerixafor-induced demar-
gination could be a more generalized effect, which occurs 
throughout the entire vascular system, which may contrib-
ute to the rapid rise of neutrophil counts in the blood after 
plerixafor treatment.
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simplistic; because the BM is the primary site of neutrophil 
production, any significant increases in circulating neutrophil 
numbers must therefore be attributed to their release from the 
BM. This overriding assumption has and may continue to 
lead to erroneous interpretations of end point studies such as 
those that relied on the quantification of neutrophil counts in 
the blood and/or BM as a readout. In the present study, we 
have used a combination of intravital imaging and in vivo 
homing assays to study the underlying cellular mechanisms of 
neutrophil mobilization in a highly compartmentalized man-
ner. We observed that G-CSF and plerixafor work through 
two distinct cellular mechanisms affecting different compart-
ments: G-CSF exerts its effects by increasing neutrophil mo-
bilization and their release from the BM, which is in agreement 
with previous studies (Ulich et al., 1988; Semerad et al., 1999; 
Martin et al., 2003; Eash et al., 2010; Köhler et al., 2011b). 
However, contrary to the current paradigm, we found that 
inhibition of CXCR4 did not have a significant impact on 
BM neutrophil activities. Instead, plerixafor augmented the 
frequency of circulating neutrophils by simultaneously in-
creasing the number of neutrophils reentering the circulation 
from the marginated pool present in the lung, as well as de-
creasing the number of neutrophils trafficking back to the 
BM, thereby increasing their retention in the blood.
It is well accepted that G-CSF–induced neutrophilia is a 
result of increased neutrophil release from the BM. This is 
established on the basis of G-CSF inducing an increase of neu-
trophils in the circulation, which is associated with a reciprocal 
decrease in the number of neutrophils in the BM (Ulich et al., 
1988; Semerad et al., 2002; Martin et al., 2003). Indeed, data 
from our intravital imaging experiments showed that G-CSF 
increases BM neutrophil motility and redistribution of neu-
trophils around BM sinusoids, as also described by a recent study 
(Köhler et al., 2011b). Furthermore, G-CSF–induced neutro-
phil egress from the BM paralleled the appearance of additional 
We finally sought to validate our plerixafor finding in a 
nonhuman primate model (Macaca fascicularis). Longitudinal 
collection of blood samples is not possible in mice; however, 
repeated sampling of blood from individual macaques permit-
ted detailed assessment of the neutrophil counts over a 4-h 
period. 0.5 mg/kg plerixafor was administered s.c. to anes-
thetized animals and simultaneous blood sampling from the 
aorta and inferior vena cava was conducted every hour for 
4 h thereafter (Fig. 9 a). Analogous to our earlier findings in 
mice, differential counting of neutrophil frequency in arterial 
and venous blood samples from two primates revealed an in-
creased number of neutrophils in arterial blood after plerixa-
for treatment in both animals (Fig. 9 b). Neutrophil release 
from the lung peaked 2–3 h after plerixafor administration 
and returned to basal levels by 4 h.
Collectively, the findings from our study are the first to 
provide direct in vivo evidence demonstrating the ability of 
CXCR4 inhibition to induce demargination of neutrophils 
from the lung microvasculature and promote reentry of these 
cells into the circulation. These data supports the concept that 
the lung is an important source of neutrophils, which can be 
mobilized readily into the peripheral blood. Our demonstra-
tion that similar neutrophil demargination also occurs in 
nonhuman primates strongly suggests that our findings also 
extend to human patients.
DISCUSSION
Neutrophils are key mediators of host defense against micro-
bial agents. The distribution of neutrophils between different 
tissue compartments is a tightly regulated process to maintain 
stable blood neutrophil counts at resting state, to allow rapid 
mobilization of neutrophils in response to inflammatory stimuli, 
and to return to a state of homeostasis after the immune re-
sponse. Current prevailing views in the scientific community 
of how blood neutrophil counts are regulated are often rather 
Figure 9. Primate lung neutrophils are released after 
plerixafor treatment. (a, Left) A schematic representation of 
the simultaneous blood sampling method used in the nonhuman 
primate model Macaca fascicularis. Arrows indicate the direc-
tion of blood flow (blue = venous blood entering the lung; red = 
arterial blood exiting the lung). X indicates the aorta and inferior 
vena cava sites of blood collection. Blood was sampled from the 
aorta and vena cava before s.c. injection of 0.5 mg/kg plerixafor 
and then at 1-h intervals for a total duration of 4 h. (b) Net neu-
trophil release from the lungs of two individual animals over a 
4-h observation period.
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our findings that plerixafor also reduced neutrophil margin-
ation in the capillary beds of skeletal muscle. CXCL12 has 
been shown to activate integrins LFA-1 and VLA-4 on CD34+ 
human stem cells (Peled et al., 2000). Given that the integrins 
play a major role in cell adhesion, it is conceivable that 
CXCR4 regulates neutrophil margination in lungs by alter-
ing integrins expression, and this warrants further investigation. 
In addition, a previous study demonstrated that plerixafor 
treatment attenuates allergic lung inflammation (Lukacs et al., 
2002). It is important for future studies to investigate the func-
tional importance of CXCR4-mediated neutrophil margin-
ation/demargination in lungs, particularly to elucidate how 
this process may influence neutrophil recruitment into the 
lung in response to inflammation/infection, as this may have 
important implications for the clinical use of plerixafor.
Although our work focused extensively on G-CSF and 
plerixafor as therapeutic agents, if viewed from the perspec-
tive of G-CSF as a naturally occurring polypeptide factor 
and plerixafor as a CXCR4 signaling blocker, our mechanis-
tic investigations have uncovered several startling conclusions 
about their physiological maintenance in dynamic equilib-
rium. This may have far-reaching consequences in how we 
traditionally perceive neutrophil and leukocyte homeostasis. 
Our current data suggests that the steady increase in neutro-
phil counts after G-CSF treatment could be mediated by dis-
tinct mechanisms that occur in different phases. In the early 
phase, mobilization of neutrophils from the BM acts as the 
main mechanism, but in the later phase, there is additional 
contribution from the demargination of neutrophils. Also, 
neutrophils in the BM become more responsive to mobiliza-
tion signals in the later phase. It is important to point out that 
we are not contesting the value of data from previous works 
but highlighting that the short-term mechanistic action of 
the chemokine receptors are more complex and surprising 
than we would expect from long-term genetic studies. For 
instance, our cotransfer experiment showed that transient in-
hibition by plerixafor was able to alter WHIM neutrophil re-
tention in blood and affect BM homing patterns in a similar 
fashion as wild-type neutrophils. Interestingly, during basal 
state, we observed a similar proportion of WHIM versus wild-
type neutrophils that had trafficked back to the BM. This was 
unexpected, as prior studies had proposed the cause of abun-
dance accumulation of mature neutrophils (myelokathexis) to 
be a result of increased neutrophil retention and homing to 
the BM (Balabanian et al., 2012). A possible explanation for 
this unexpected finding is the difference in the mechanisms 
regulating the process of neutrophil homing and egress in 
WHIM mice. It is conceivable that, under resting conditions, 
a gain-of-function in CXCR4 plays a functional dominant 
role in the chemotaxis and chemokinesis of neutrophils in the 
BM and a much lesser role in the chemotactic homing of 
neutrophils to the BM. This notion is supported by our imag-
ing data which showed that despite G-CSF causing an in-
crease in motility, WHIM neutrophil egress remained deficient 
and plerixafor treatment also had minimal effect on BM neu-
trophil egress. Thus, even in WHIM mice, the consequence of 
neutrophils in circulation, demonstrating that these cells are 
predominantly of BM origin. Of importance, our study has 
directly demonstrated for the first time that neutrophils that 
have trafficked back to the BM are able to maintain their ca-
pacity to reenter the circulation in response to G-CSF treat-
ment. Thus, the BM may serve as a dynamic reservoir for 
storing and re-release of circulating neutrophils in response 
to fluctuating G-CSF levels, leading to implications in our 
understanding of the role of G-CSF in basic physiology, as 
G-CSF is produced in response to stress signals. Numerous 
prior studies have reported a role for CXCR4 in the reten-
tion of neutrophils in the BM (Martin et al., 2003; Eash et al., 
2009; Petty et al., 2009; Eash et al., 2010). It has therefore been 
presumed that neutrophilia induced by CXCR4 blockade/
plerixafor in both mice and human, results from increased 
neutrophil release from the BM (Martin et al., 2003; Dale 
et al., 2011; McDermott et al., 2011; Balabanian et al., 2012). 
However, there is little direct evidence that plerixafor can act 
as a BM neutrophil mobilizing agent in vivo. In fact, only a 
single ex vivo study of the perfused murine femoral BM has 
reported that plerixafor treatment can increase neutrophil 
release from this compartment (Martin et al., 2003). Because 
this study quantified neutrophils only in the femoral vein 
perfusate after plerixafor administration via the femoral ar-
tery, it was unclear whether the increase in neutrophil num-
bers observed in this model originated from the intravascular 
pool or the BM. In the current study, our in vivo imaging 
analyses revealed that plerixafor treatment did not exert a sig-
nificant impact on BM neutrophil activity in either the en-
dogenous or the cell transfer model. Despite exerting little 
effect on neutrophil mobilization from the BM, plerixafor 
still induced a substantial increase in circulating neutrophil 
numbers, indicating that CXCR4 inhibition may mobilize 
neutrophils to the blood from additional compartments other 
than the BM.
It has long been believed that the lung has the capacity 
to withdraw neutrophils from the blood into the pulmonary 
microvasculature and can deliver these cells back into the cir-
culation when required (Bierman et al., 1952a). Indeed, neu-
trophils are rapidly released from the lung into the circulation 
within only seconds of epinephrine administration, indicating 
that the lung can serve as an important reservoir of these cells 
(Bierman et al., 1952b). Our own data revealed that CXCR4 
inhibition triggers the release of neutrophils from the lung in 
both mice and nonhuman primates. The primate data are 
consistent with our intravital lung imaging data obtained in 
mice, which showed that fewer neutrophils are marginated in 
the lung after plerixafor treatment. Thus, in addition to its re-
ported role in mediating the return of senescent neutrophils 
to the BM (Martin et al., 2003), our study identifies a novel 
role for CXCR4 in controlling neutrophil margination in the 
lung. It is tempting to speculate that the regulation of neutro-
phil removal from circulation by CXCR4 through the mar-
gination process is not restricted to the lung but represents a 
more generalized mechanism of blood neutrophil removal 
throughout the entire vascular system. This is supported by 
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evidence-based evaluation of drug action will facilitate the 
design of optimally tailored treatment regimens for neutro-
phil-related diseases. Further understanding of the biological 
function of the differential sources of neutrophils will be of 
particular importance for future studies as these neutrophils 
may possess distinct homing/adhesion pattern and/or cytokine 
secretion profile (Mantovani et al., 2011; Pillay et al., 2012).
METHODS AND MATERIALS
Mice. Mice 8–12 wk old were bred in the Biological Resource Centre 
(BRC) of A*STAR, Singapore, or in the University of Calgary animal facility 
and were maintained under specific pathogen-free conditions. LysM-GFP 
mice express enhanced GFP under the LysM promoter and were provided by 
T. Graf (Centre for Genomic Regulation, Barcelona, Spain; Faust et al., 2000). 
mT/mG mice (Muzumdar et al., 2007) and CX3CR1 mice (Jung et al., 
2000) were obtained from JAX mice. Gain-of-function CXCR4mut mice 
were generated as previously described (Balabanian et al., 2012). All mouse 
experiments were performed with the approval of the Institutional Animal 
Care and Use Committee of the BRC and the University of Calgary Animal 
Care Committee.
Neutrophil mobilizing reagents. Mice were injected s.c. with 250 µg/kg 
of recombinant human G-CSF (Roche; Semerad et al., 2002) or 5 mg/kg 
plerixafor (AMD 3100, Sigma-Aldrich; Broxmeyer et al., 2005; Eash et al., 
2010). Control mice were injected s.c. with sterile PBS (Gibco). The dos-
ages for G-CSF and plerixafor administered in mice had been optimized 
(Broxmeyer et al., 2005) to have comparable effects to doses administered in 
human clinical studies.
Generation of BM chimeras. Chimeric mice were generated via irradia-
tion and BM transfer as described previously (Hoeffel et al., 2012). In brief, 
6-wk-old mice were lethally irradiated with two doses of 550 rad spaced 3 h 
apart. BM cells were harvested from donor mice under sterile conditions and 
recipient mice were injected retro-orbitally with 5 × 106 BM cells within 
24 h of irradiation. Recipient mice were maintained under SPF conditions 
for 8 wk before use in intravital multiphoton microscopy experiments.
Intravital multiphoton imaging of skull BM. Skull BM imaging was 
performed with minor modifications to published protocols (Mazo et al., 
1998; Lo Celso et al., 2011). Mice were anaesthetized with a cocktail of 
150 mg/kg ketamine and 10 mg/kg xylazine and immobilized on a custom-
made stage. A heating pad affixed to the stage was used to maintain animal 
temperature at 37°C. A small area of skin on the skull was removed to expose 
the skull BM. The exposed skull was superfused with sterile PBS, covered 
with a glass coverslip, and visualized with a LaVision TriM Scope II micro-
scope (LaVision BioTec), equipped with a 20× 1.4 NA WI objective lens and 
a Coherent Chameleon pulsed infrared laser. Experiments were performed at 
880 nm excitation unless otherwise specified. Images were acquired using a 
4-µm z-step size with an approximate z-depth of 50 µm. Image stacks were 
acquired every 20 s over a 2-h imaging period. To label blood vessels in vivo, 
mice were retro-orbitally injected with 4 mg TRITC-conjugated 155-kD 
dextran (Sigma-Aldrich) in 200 µl saline (Li et al., 2012). Imaging of the tibial 
BM was performed as previously described (Köhler et al., 2011a).
Image analysis. Images were transformed into time series movies and 
analyzed using IMARIS image analysis software (Bitplane). Tracking of cell 
motility in three dimensions was performed in a semiautomated manner as 
described previously (Ng et al., 2008, 2011). The mean/median and instanta-
neous migration velocities were typically obtained from 121 consecutive 
frames of video. To quantitate the endogenous neutrophil egress, the relative 
GFP fluorescence intensity was determined in specified regions of the mar-
row space using the surface function in surpass mode in IMARIS. For the 
analysis of experimental model 1 (neutrophil egress), the number of transmi-
grated GFP+ cells was quantified manually.
increased circulating neutrophils with plerixafor treatment ap-
pears to be largely dependent on their decreased BM homing. 
To the best of our knowledge, our work is the first to demon-
strate that constitutive CXCR4 signaling, as demonstrated in 
WHIM mice, promotes neutrophil retention in the BM (de-
fective neutrophil egress) without affecting the efficiency of 
neutrophil homing (working neutrophil ingress), further high-
lighting the complexities of CXCR4 in these processes.
The concept of marginated pools as neutrophil reservoirs 
have been around for a long time, but this fundamentally im-
portant concept remains underappreciated. Our study is the 
first to demonstrate the crucial role of CXCR4–CXCL12 
interactions in regulating the pulmonary marginated neutro-
phil pool, and that drastic change in the circulating neutrophil 
numbers can be achieved through mobilizing neutrophils from 
alternative reservoirs other than the BM, and hence demon-
strates the importance of studying leukocyte homeostasis in 
an integrated manner that takes into consideration their com-
partmentalizations. Of interest, a previous study showed that 
CXCL12 can act as a vasoconstrictor and that this effect can 
be inhibited by plerixafor (Mieno et al., 2006). Thus, it is pos-
sible that plerixafor may induce changes in the cardiac output, 
which may be a contributing factor for the demargination of 
neutrophils in the lung.
From a clinical point of view, we have provided mechanistic 
insights into how G-CSF and plerixafor, despite their differ-
ing influences on neutrophil activity, consequently translate 
into increases in the number of circulating neutrophils. Our 
finding here with plerixafor also emphasizes that neutrophil 
mobilizing agents should be evaluated based on a comprehen-
sive integrated approach, in which the neutrophil pool of dif-
ferent body compartments need to be considered holistically. 
Our current data shows that plerixafor treatment was able 
to induce neutrophil release from the lung up to 4 h after ad-
ministration, and prevented neutrophils from homing back to 
the BM for up to 3 h. Despite the continued supply of circu-
lating neutrophils from lung demargination, it was thus inter-
esting to note that the overall circulating neutrophil numbers 
peaked at 1–2 h but returned to near basal levels by 4 h after 
plerixafor treatment. In contrast, we found that the rate of neu-
trophil trafficking back to the BM inversely correlated with 
neutrophil retention in the blood and was the stronger pre-
dictor of circulating neutrophil counts. Together, these results 
suggest that the plerixafor-induced neutrophil retention in 
the blood might be the primary mechanism responsible for 
the increased circulating neutrophil numbers detected, and 
that the demargination of neutrophils from the lung may 
play an important role only in the early stages after plerixafor 
treatment. Future studies should focus on examining whether 
plerixafor induces the presence of distinct populations of cir-
culating neutrophils by changing their homing/margination 
patterns. Of particular interest, plerixafor is also used as a he-
matopoietic stem cell (HSC) mobilizing agent (Broxmeyer 
et al., 2005). In light of our current findings, it will be interest-
ing to determine whether plerixafor-induced HSC mobiliza-
tion derives solely from the BM. In conclusion, we believe that 
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mice were anaesthetized with a cocktail of ketamine and xylazine and placed 
on a heater. Tracheostomy and catheterization of the jugular vein were per-
formed surgically before the mice were connected to a mechanical ventilator 
(Mini Vent; HSE) and the lung exposed. To immobilize the lung, a custom-
made vacuum window was positioned over the lung surface for the applica-
tion of a negative pressure (40 mm Hg). The lung microvasculature was 
visualized at 10× magnification using a spinning-disk multichannel fluores-
cence intravital microscope (Quorum). Cell activity in the lung microvascu-
lature was assessed using 488 and 635 nm lasers for excitation (typically 1-s 
duration) and then visualized using the appropriate long-pass filters (Sem-
rock). A back-thinned electron-multiplying charge-coupled device camera 
(512 × 512 pixels; C9100-13; Hamamatsu) was used for fluorescence detec-
tion (Yipp et al., 2012). For delineation of the lung vasculature, mice were 
intravenously injected with 40 µg Alexa Fluor 647–conjugated bovine serum 
albumin (Invitrogen). Five different fields were recorded for 5 min and then 
analyzed to determine the total number of neutrophils per field. Neutrophils 
were defined as adherent if they remained stationary in the field for the en-
tire imaging period. Data acquisition and analysis were performed using 
Volocity software (Perkin Elmer).
Intravital multiphoton imaging of skeletal muscle. The tibial anterior 
muscle was surgically prepared for imaging the skeletal muscle. LysM-GFP 
mice were anaesthetized with a cocktail of 150 mg/kg ketamine and 10 mg/kg 
xylazine. The left jugular vein was cannulated to allow the administration of 
50 µg Evan’s blue (Sigma-Aldrich) in 50 µl saline to label blood vessels in 
vivo. The mouse was subsequently immobilized on a custom-made stage and 
a heat pad was used to maintain the body temperature. To expose the skeletal 
muscle for imaging, a small area of skin was removed and loose dermal con-
nective tissue was cleared to allow better visualization of the intact skeletal 
muscle vasculature. The exposed area was superfused with sterile PBS and 
sealed with a coverslip, with additional heating provided for the exposed mus-
cle at 37°C. Experiments were performed at 950 nm excitation and images 
were acquired using a 5-µm z-step size with an approximate z-depth of 120 µm. 
Image stacks were acquired every 30 s over a 1-h imaging period.
Determination of circulating neutrophils in nonhuman primates. 
All experiments on adult female Macaca fascicularis nonhuman primates (2.5 kg 
and 3.2 kg, respectively) were performed at the SingHealth Experimental 
Medicine Centre (accredited by the Association for Assessment and Accredi-
tation of Laboratory Animal Care) under approval #2012/SHS/692 from the 
Institutional Animal Care and Use Committee of Singapore. Mid-line lapa-
rotomy was performed under general anesthesia, and the retro-peritoneum 
was reflected along the mesenteric insertion. The descending abdominal 
aorta and inferior vena cava were identified and 1 ml blood was collected 
from each using a 25G needle 10 min before s.c. administration of 0.5 mg/kg 
plerixafor and at hourly intervals thereafter. Blood leukocyte counts were 
performed using a Hematology Analyzer (Beckman-Coulter).
Statistical analysis. Statistical analyses were conducted using Student’s 
t test (normally distributed data) or one-way analysis of variance (ANOVA). 
P-values <0.05 were considered significant.
Online supplemental material. Fig. S1 shows assessment of leukocyte 
GFP expression in the BM of LysM-GFP mice. Video 1 shows neutrophil 
behavior in the skull BM. Video 2 shows dynamic behavior of neutrophil in 
the BM in response to G-CSF or plerixafor treatment. Video 3 shows that 
G-CSF increases neutrophil egress from the BM. Video 4 shows that plerixa-
for does not increase the number of neutrophil egress from the BM. Video 5 
shows basal levels of neutrophil egress from the BM. Video 6 shows that 
plerixafor pretreatment augments KC-induced neutrophil egress from the 
BM. Video 7 shows neutrophil trafficking to the BM. Video 8 shows intravital 
imaging of neutrophils in the lung. Video 9 shows intravital imaging of neu-
trophils in skeletal muscle. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20130056/DC1.
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Murine BM cell isolation and transfer. The right femurs of LysM-GFP 
mice were removed and the femoral BM was harvested by flushing with 10 ml 
PBS containing 3% FCS. RBCs were lysed using commercial-grade RBC 
lysis buffer (eBioscience) and the remaining cells were resuspended in sterile 
PBS. In some experiments, 5 × 106 LysM-GFP+ BM cells were delivered 
retro-orbitally or by catheterization and infusion via the left jugular vein. 
In another set of experiments, both the femur and tibia of WHIM-LysM-
GFP and WT-mT/mG mice were removed and BM cells were harvested 
as described earlier. This was then followed by negatively selecting Ly6G+ 
cells from BM cells with the EasySep mouse neutrophil enrichment kit 
(STEMCELL Technologies, Inc.). 2.5 × 106 neutrophils from WHIM-LysM-
GFP+ and WT-mT/mG+ cells were subsequently mixed and delivered 
retro-orbitally.
Measurement of neutrophil numbers by flow cytometry. Cells isolated 
from the femur and/or blood was collected for analysis by flow cytome-
try. Samples were subjected to RBC lysis followed by incubation with block-
ing buffer (3% FCS and 5% rat serum in PBS) for 10 min. Cells were stained 
with the following antibodies: PE-conjugated CD115 (clone AFS98), PerCP-
Cy5.5–conjugated CD11b (clone M1/70), and APC-Cy7–conjugated CD45 
(clone 30-F11) from eBioscience; and APC-conjugated Ly-6G (clone 1A8) 
from BioLegend. Cells were stained with DAPI (Invitrogen) to assess cell 
viability and CountBright absolute counting beads (Invitrogen) were added 
before acquisition to enable calculation of absolute cell numbers. All sam-
ples were acquired using a FACSCanto II flow cytometer (BD) equipped 
with FACSDiva software. Data analysis was performed using FlowJo soft-
ware (Tree Star).
Assessment of circulating neutrophils at different sites of blood 
collection. Mice were anaesthetized with a cocktail of 150 mg/kg ketamine 
and 10 mg/kg xylazine and placed on a heating pad at 37°C. The right 
carotid artery was cannulated using a previously described method (Duyverman 
et al., 2012). In brief, a midline incision was made on the neck and the glands 
were separated sideways to expose the trachea before the surrounding tissues 
were cleared to expose the underlying carotid artery. A polyethylene 10 tubing 
(inner diameter: 0.28 mm; outer diameter: 0.61 mm) was drawn to reduce 
the diameter at the tip for cannulation. A microvascular clamp was applied to 
the artery before insertion of the EDTA-filled tubing. The cannula was se-
cured with a surgical suture and then the clamp was released to allow blood 
collection into an Eppendorf tube. Blood was then immediately withdrawn 
from the inferior vena cava using a 26G needle attached to a syringe prefilled 
with EDTA. Blood samples from different sites were prepared for FACS 
analysis as described earlier. In experiments using epinephrine as a positive 
control, epinephrine bitartrate salts (Sigma-Aldrich) were dissolved in saline 
and administered intraperitoneally at 1 mg/kg.
Flow cytometry analysis of CD31+GFP+ cells in lungs. Cells isolated 
from PBS-perfused lungs from wild-type and CXCL12-GFP mice were col-
lected for analysis by flow cytometry. Lungs were harvested, minced, and 
incubated with 1 U/ml liberase (Roche) and 12 mU/ml DNase I (Sigma- 
Aldrich) in RPMI for 30 min at 37°C, pipetting every 5 min. Single cell sus-
pensions were then stained with APC-conjugated and APC-Cy7–conjugated 
antibodies against CD31 and CD45. CD31+GFP+ cells were analyzed from 
the DAPI-negative and CD45-negative fraction.
Immunofluorescence analysis of CXCL12-GFP lungs. CXCL12-GFP 
mice were perfused with PBS followed by 2% paraformaldehyde. Lungs were 
harvested and placed in 2% paraformaldehyde overnight, followed by gradu-
ally preserving in 15 and 30% sucrose, before finally freezing in O.C.T. 
medium. 8-µm sections were hydrated in PBS for 10 min and mounted 
with Vectashield mounting media with DAPI. Images were acquired and ana-
lyzed with a confocal microscope (SPE; Leica) using LAS AF reprocessing 
software (Leica).
Spinning-disk confocal intravital imaging of lung. The detailed set-up 
for lung imaging can be found elsewhere (Looney et al., 2011). In brief, 
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Video 9. intravital imaging of neutrophils in skeletal muscle.Time-
lapsesequencesofmaximumintensityprojectiondepictingthebehavior
ofGFP+neutrophilsinLysM-GFPmiceinresponsetoPBS(control)or
plerixafortreatment.Vasculatureislabeledwithintravenousinjectionof
Evan’sblue.Elapsedtimeisshowninhours:minutes:seconds.
